Observational studies all agree that long term use of NSAIs decreases the risk and delays the onset of Alzheimer's disease (AD). The action mechanism seems to be a modulation of gamma-secretases, well through cyclooxigenase enzymes well inducting an allosteric change in them. Studies in animal models show a clear decrease in the amyloid neuropathology while clinical trials have not reached to show efficacy by the moment although there are 4 clinical trials on going so we should still keep open the possibility for some of them to finally get the approval for the treatment of AD. Disagreement exists between case-control observational studies that show that those patients who were put on statins had a lower risk of dementia and cohorts observational studies that did not find any risk decrease after 1-2 years of follow-up. The action mechanism may be related to the statins' immunomoduloraty activity, to interaction with secretases or interaction with the isoprenoid way. The most successful statin in clinical experimentation is atorvastatin and a clinical trial with this molecule is still on going.
|Translated title of the contribution||NSAIs and statins for the treatment of Alzheimer's disease|
|Journal||Archivos de Medicina|
|State||Published - Jun 5 2006|
- Alzheimer's disease
ASJC Scopus subject areas